Melanoma vaccines

Details

Serval ID
serval:BIB_554D0E83531E
Type
A part of a book
Publication sub-type
Chapter: chapter ou part
Collection
Publications
Institution
Title
Melanoma vaccines
Title of the book
Targeted Therapeutics in Melanoma
Author(s)
Romero P., Speiser D.E.
Publisher
Springer
Address of publication
New York
ISBN
978-1-61779-406-3
Publication state
Published
Issued date
2012
Editor
Gajewski T.F., Hodi F.S.
Series
Current clinical oncology
Pages
207-232
Language
english
Abstract
Many vaccines have been very successful. They can protect from many different infectious diseases, and thus contribute enormously to public health. The majority of successful vaccines induce neutralizing antibodies, which are essential for protection from disease, by the inhibition of microbe invasion and spread through the body, via extracellular compartments, or by neutralization of toxins. In contrast to infectious diseases, the pathological process in cancer is primarily intracellular. Immunity to cancer depends mainly on T cells which are capable of identifying and eliminating abnormal cells, via recognition of peptide antigens presented by major histocompatibility complex molecules at the cell surface. In some instances, tumor-specific antibodies can contribute to immune defense against cancer. Unfortunately, for many solid tumors (including melanoma), this mechanism is insufficient. Nevertheless, the search for cancer-neutralizing antibodies continues, similar to, e.g., HIV neutralizing antibodies. In this chapter, we focus on the development of T cell vaccines, a great challenge but also a promising approach as a new therapy for melanoma, other cancers, and intracellular pathogens
Web of science
Create date
23/01/2013 15:39
Last modification date
20/08/2019 15:09
Usage data